Cigna to remove AbbVie’s Humira from some drug reimbursement lists next year
4 months, 2 weeks ago

Cigna to remove AbbVie’s Humira from some drug reimbursement lists next year

Live Mint  

By Patrick Wingrove Aug 26 - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead. Although 10 Humira biosimilars have launched in the U.S. since January 2023 from drugmakers including Amgen and Pfizer, AbbVie has managed to retain most of the market by negotiating favorable positions on insurance drug coverage lists managed by these middlemen. Cigna in June made Humira biosimilars available with no out-of-pocket payment to eligible U.S. patients using its specialty pharmacy, but AbbVie lost virtually no market share as a result. Optum Rx did not immediately respond to a request for comment on whether it planned to remove Humira from any reimbursement lists next year.

Market Share Drug Lists Humira Cigna  lists  reimbursement  pharmacy  cigna  abbvies  drug  unit  market  share  remove  managed  humira  versions

History of this topic

California insurer experiments with drug giveaway, bypassing secret fees
3 months, 1 week ago

California insurer experiments with drug giveaway, bypassing secret fees

LA Times  

Blue Shield of California is set to offer Humira, one of the world’s top-selling drugs, for free. “We want to be able to present the price to our membership so that they can make the choice.” There’s also a profit motive: Blue Shield of California currently spends more than $100 million a year on Humira, Gibbs said, more than any …

Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio
1 year, 1 month ago

Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

Associated Press  

AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth. Elahere brought in $105.2 million in revenue in …

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice
1 year, 3 months ago

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

LA Times  

Humira has enjoyed high-priced U.S. exclusivity for 20 years, making it the best-selling drug in history. How AbbVie maintains market share One of AbbVie’s strategies was to warn health plans that if they recommended biosimilars over Humira they would lose rebates on purchases of Skyrizi and Rinvoq, two drugs with no generic imitators that are each listed at about $120,000 …

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance
1 year, 6 months ago

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Associated Press  

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. Instead, it depends on their prescription drug coverage, which might still bring large bills until a plan’s deductible is met. PBMs negotiate confidential deals with drugmakers that can influence whether a biosimilar …

Discover Related